199 related articles for article (PubMed ID: 33422487)
1. LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin.
Taheri M; Shoorei H; Tondro Anamag F; Ghafouri-Fard S; Dinger ME
Exp Mol Pathol; 2021 Dec; 123():104602. PubMed ID: 33422487
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines.
Yu ZW; Zhong LP; Ji T; Zhang P; Chen WT; Zhang CP
Oral Oncol; 2010 Apr; 46(4):317-22. PubMed ID: 20219416
[TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
4. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
5. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
6. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer.
Zhang YF; Li CS; Zhou Y; Lu XH
Life Sci; 2020 Mar; 244():117280. PubMed ID: 31926239
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
Guo J; Pan H
Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNAs as biotargets in cisplatin-based drug resistance.
Abu N; Hon KW; Jeyaraman S; Jamal R
Future Oncol; 2018 Dec; 14(29):3085-3095. PubMed ID: 30468082
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
Xu YH; Tu JR; Zhao TT; Xie SG; Tang SB
Int J Oncol; 2019 Jan; 54(1):295-305. PubMed ID: 30431074
[TBL] [Abstract][Full Text] [Related]
10. Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a.
Tang H; Han X; Li M; Li T; Hao Y
Biochimie; 2019 Jul; 162():134-143. PubMed ID: 31029744
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.
Li C; Fan K; Qu Y; Zhai W; Huang A; Sun X; Xing S
J Cell Physiol; 2020 Apr; 235(4):3721-3730. PubMed ID: 31583720
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
15. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
16. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
17. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell.
Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
PLoS One; 2013; 8(5):e65309. PubMed ID: 23741487
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
19. LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy.
Huang FX; Chen HJ; Zheng FX; Gao ZY; Sun PF; Peng Q; Liu Y; Deng X; Huang YH; Zhao C; Miao LJ
Int J Oncol; 2019 Jan; 54(1):339-347. PubMed ID: 30387831
[TBL] [Abstract][Full Text] [Related]
20. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
Yang X; Meng L; Zhong Y; Hu F; Wang L; Wang M
Aging (Albany NY); 2021 Jan; 13(2):2864-2884. PubMed ID: 33418541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
